Avion and Acella Pharmaceuticals Provide Statement Related to Avondale Drug Pricing News | PR Newswire

Avion and Acella were made aware of the recent 800 percent price increase for Avondale’s version of niacin, going from $32.46 to $295 per 100 pills.  Avion and Acella pharmaceuticals are led by CEO, Art Deas.  Mr. Deas has confirmed that both companies were unaware of the Avondale pricing activity and that neither company has any relationship or communication with Avondale or its CEO Mark Pugh.

“We would like to make clear that, on March 1, 2016, Mr. Pugh was removed as an officer and member of the Board of Managers of both Acella Pharmaceuticals and Avion Pharmaceuticals. Since that time, Mr. Pugh has not been involved in the operation or management of either company. Moreover, neither Acella Pharmaceuticals nor Avion Pharmaceuticals, or any of their officers, have any connection with Avondale Pharmaceuticals, Acrogen Pharmaceuticals or their reported pricing strategies,” added Deas.

Read complete article here:

Avion and Acella Pharmaceuticals Provide Statement Related to Avondale Drug Pricing News.